Usefulness of non-enzymatic post-translational modification derived products (PTMDPs) as biomarkers of chronic diseases

Journal of Proteomics

Volumn 92, Issue , 2013, Pages 228-238

  Gillery, Philippe ^a,b   Jaisson, Stéphane ^a,b  

^a AMERICAN MEMORIAL HOSPITAL   (France)

^b UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

Biomarker; Carbamylation; Glycoxidation; Oxidation; Protein molecular aging; Proteomics

Indexed keywords

3 NITROTYROSINE; ADVANCED OXIDATION PROTEIN PRODUCT; GLYCERALDEHYDE 3 PHOSPHATE; GLYCOSYLATED ALBUMIN; GLYCOSYLATED HEMOGLOBIN; HOMOCITRULLINE; ISOCYANATE; LOW DENSITY LIPOPROTEIN; METHIONINE; METHIONINE SULFOXIDE; PEROXYNITRITE; PROTEIN HYDROLYSATE; REACTIVE OXYGEN METABOLITE;

ANALYTIC METHOD; ATHEROSCLEROSIS; BODY FLUID; BONE MINERALIZATION; CARBAMOYLATION; CARBONYLATION; CARDIOVASCULAR RISK; CHEMICAL REACTION; CHLORINATION; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL PRACTICE; DIABETES MELLITUS; DISEASE SEVERITY; FLUORESCENCE ANALYSIS; GLYCATION; GLYCEMIC CONTROL; GOLD STANDARD; HEMODIALYSIS; HUMAN; LIPID PEROXIDATION; MASS SPECTROMETRY; MICHAEL ADDITION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; OXIDATIVE STRESS; PEPTIDE MAPPING; PEROXIDATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CARBONYLATION; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; PROTEOMICS; RESPIRATORY BURST; RESPIRATORY CHAIN; RETINOPATHY; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS;

BIOMARKER; CARBAMYLATION; GLYCOXIDATION; OXIDATION; PROTEIN MOLECULAR AGING; PROTEOMICS;

AGING; ANIMALS; BIOLOGICAL MARKERS; CHRONIC DISEASE; HUMANS; MASS SPECTROMETRY; OXIDATION-REDUCTION; PROTEIN CARBONYLATION; PROTEIN MODIFICATION, TRANSLATIONAL; PROTEOMICS;

EID: 84887019466     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.02.015     Document Type: Review

References (114)

1. Ahmed N., Thornalley P.J. Advanced glycation endproducts: what is their relevance to diabetic complications?. Diabetes Obes Metab 2007, 9:233-245.
2. Soskic V., Groebe K., Schrattenholz A. Nonenzymatic posttranslational protein modifications in ageing. Exp Gerontol 2008, 43:247-257.
3. Baynes J.W. The clinical chemome: a tool for the diagnosis and management of chronic disease. Clin Chem 2004, 50:1116-1117.
4. Meerwaldt R., Links T., Zeebregts C., Tio R., Hillebrands J.L., Smit A. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc Diabetol 2008, 7:29.
5. Jaisson S., Gillery P. Evaluation of nonenzymatic posttranslational modification-derived products as biomarkers of molecular aging of proteins. Clin Chem 2010, 56:1401-1412.
6. Cannizzo E.S., Clement C.C., Sahu R., Follo C., Santambrogio L. Oxidative stress, inflamm-aging and immunosenescence. J Proteomics 2011, 74:2313-2323.
7. Dasuri K., Zhang L., Keller J.N. Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis. Free Radic Biol Med 2012, 10.1016/j.freeradbiomed.2012.09.016.
8. Oberg B.P., McMenamin E., Lucas F.L., McMonagle E., Morrow J., Ikizler T.A., et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004, 65:1009-1016.
9. Yang H., Jin X., Kei Lam C.W., Yan S.K. Oxidative stress and diabetes mellitus. Clin Chem Lab Med 2011, 49:1773-1782.
10. Grimsrud P.A., Xie H., Griffin T.J., Bernlohr D.A. Oxidative stress and covalent modification of protein with bioactive aldehydes. J Biol Chem 2008, 283:21837-21841.
11. Selmeci L. Advanced oxidation protein products (AOPP): novel uremic toxins, or components of the non-enzymatic antioxidant system of the plasma proteome?. Free Radic Res 2011, 45:1115-1123.
12. Witko-Sarsat V., Nguyen-Khoa T., Jungers P., Drueke T.B., Descamps-Latscha B. Advanced oxidation protein products as a novel molecular basis of oxidative stress in uraemia. Nephrol Dial Transplant 1999, 14(Suppl. 1):76-78.
13. Moller I.M., Rogowska-Wrzesinska A., Rao R.S. Protein carbonylation and metal-catalyzed protein oxidation in a cellular perspective. J Proteomics 2011, 74:2228-2242.
14. Sayre L.M., Lin D., Yuan Q., Zhu X., Tang X. Protein adducts generated from products of lipid oxidation: focus on HNE and one. Drug Metab Rev 2006, 38:651-675.
15. Negre-Salvayre A., Coatrieux C., Ingueneau C., Salvayre R. Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. Br J Pharmacol 2008, 153:6-20.
16. Tessier F.J. The Maillard reaction in the human body. The main discoveries and factors that affect glycation. Pathol Biol (Paris) 2010, 58:214-219.
17. Sacks D.B., Bruns D.E., Goldstein D.E., Maclaren N.K., McDonald J.M., Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002, 48:436-472.
18. Busch M., Franke S., Ruster C., Wolf G. Advanced glycation end-products and the kidney. Eur J Clin Invest 2010, 40:742-755.
19. Rabbani N., Thornalley P.J. Glyoxalase in diabetes, obesity and related disorders. Semin Cell Dev Biol 2011, 22:309-317.
20. Rabbani N., Thornalley P.J. The dicarbonyl proteome: proteins susceptible to dicarbonyl glycation at functional sites in health, aging, and disease. Ann N Y Acad Sci 2008, 1126:124-127.
21. Thornalley P.J., Battah S., Ahmed N., Karachalias N., Agalou S., Babaei-Jadidi R., et al. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 2003, 375:581-592.
22. Lyons T.J. Glycation, carbonyl stress, EAGLEs, and the vascular complications of diabetes. Semin Vasc Med 2002, 2:175-189.
23. Jaisson S., Pietrement C., Gillery P. Carbamylation-derived products: bioactive compounds and potential biomarkers in chronic renal failure and atherosclerosis. Clin Chem 2011, 57:1499-1505.
24. Kraus L.M., Kraus A.P. Carbamoylation of amino acids and proteins in uremia. Kidney Int Suppl 2001, 78:S102-S107.
25. Wang Z., Nicholls S.J., Rodriguez E.R., Kummu O., Horkko S., Barnard J., et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007, 13:1176-1184.
26. Roberts J.M., Veres P.R., Cochran A.K., Warneke C., Burling I.R., Yokelson R.J., et al. Isocyanic acid in the atmosphere and its possible link to smoke-related health effects. Proc Natl Acad Sci U S A 2011, 108:8966-8971.
27. Monnier V.M., Sell D.R., Genuth S. Glycation products as markers and predictors of the progression of diabetic complications. Ann N Y Acad Sci 2005, 1043:567-581.
28. Monnier V.M., Sell D.R., Strauch C., Sun W., Lachin J.M., Cleary P.A., et al. The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes. J Diabetes Complications 2012, 10.1016/j.jdiacomp.2012.10.004.
29. Meerwaldt R., Hartog J.W., Graaff R., Huisman R.J., Links T.P., den Hollander N.C., et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005, 16:3687-3693.
30. Zilin S., Naifeng L., Bicheng L., Jiping W. The determination of AGE-peptides by flow injection assay, a practical marker of diabetic nephropathy. Clin Chim Acta 2001, 313:69-75.
31. Balion C.M., Draisey T.F., Thibert R.J. Carbamylated hemoglobin and carbamylated plasma protein in hemodialyzed patients. Kidney Int 1998, 53:488-495.
32. Apostolov E.O., Shah S.V., Ok E., Basnakian A.G. Quantification of carbamylated LDL in human sera by a new sandwich ELISA. Clin Chem 2005, 51:719-728.
33. Izuhara Y., Miyata T., Ueda Y., Suzuki D., Asahi K., Inagi R., et al. A sensitive and specific ELISA for plasma pentosidine. Nephrol Dial Transplant 1999, 14:576-580.
34. Weber D., Kneschke N., Grimm S., Bergheim I., Breusing N., Grune T. Rapid and sensitive determination of protein-nitrotyrosine by ELISA: application to human plasma. Free Radic Res 2012, 46:276-285.
35. Zhang X., Frischmann M., Kientsch-Engel R., Steinmann K., Stopper H., Niwa T., et al. Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients. Clin Chem Lab Med 2005, 43:503-511.
36. Onorato J.M., Thorpe S.R., Baynes J.W. Immunohistochemical and ELISA assays for biomarkers of oxidative stress in aging and disease. Ann N Y Acad Sci 1998, 854:277-290.
37. Shibayama R., Araki N., Nagai R., Horiuchi S. Autoantibody against N(epsilon)-(carboxymethyl)lysine: an advanced glycation end product of the Maillard reaction. Diabetes 1999, 48:1842-1849.
38. Delporte C., Franck T., Noyon C., Dufour D., Rousseau A., Madhoun P., et al. Simultaneous measurement of protein-bound 3-chlorotyrosine and homocitrulline by LC-MS/MS after hydrolysis assisted by microwave: application to the study of myeloperoxidase activity during hemodialysis. Talanta 2012, 99:603-609.
39. Jaisson S., Gorisse L., Pietrement C., Gillery P. Quantification of plasma homocitrulline using hydrophilic interaction liquid chromatography (HILIC) coupled to tandem mass spectrometry. Anal Bioanal Chem 2012, 402:1635-1641.
40. Teerlink T., Barto R., Ten Brink H.J., Schalkwijk C.G. Measurement of Nepsilon-(carboxymethyl)lysine and Nepsilon-(carboxyethyl)lysine in human plasma protein by stable-isotope-dilution tandem mass spectrometry. Clin Chem 2004, 50:1222-1228.
41. Bollineni R., Hoffmann R., Fedorova M. Identification of protein carbonylation sites by two-dimensional liquid chromatography in combination with MALDI- and ESI-MS. J Proteomics 2011, 74:2338-2350.
42. Lapolla A., Fedele D., Traldi P. The role of mass spectrometry in the study of non-enzymatic protein glycation in diabetes. Mass Spectrom Rev 2000, 19:279-304.
43. Niwa T. Mass spectrometry for the study of protein glycation in disease. Mass Spectrom Rev 2006, 25:713-723.
44. Ahmed N., Thornalley P.J. Peptide mapping of human serum albumin modified minimally by methylglyoxal in vitro and in vivo. Ann N Y Acad Sci 2005, 1043:260-266.
45. Bollineni R., Fedorova M., Hoffmann R. Identification of carbonylated peptides by tandem mass spectrometry using a precursor ion-like scan in negative ion mode. J Proteomics 2011, 74:2351-2359.
46. Kislinger T., Humeny A., Peich C.C., Becker C.M., Pischetsrieder M. Analysis of protein glycation products by MALDI-TOF/MS. Ann N Y Acad Sci 2005, 1043:249-259.
47. Lapolla A., Fedele D., Seraglia R., Traldi P. The role of mass spectrometry in the study of non-enzymatic protein glycation in diabetes: an update. Mass Spectrom Rev 2006, 25:775-797.
48. Priego Capote F., Sanchez J.C. Strategies for proteomic analysis of non-enzymatically glycated proteins. Mass Spectrom Rev 2009, 28:135-146.
49. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
50. Sacks D.B., Arnold M., Bakris G.L., Bruns D.E., Horvath A.R., Kirkman M.S., et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2011, 34:61-99.
51. Koga M., Hashimoto K., Murai J., Saito H., Mukai M., Ikegame K., et al. Usefulness of glycated albumin as an indicator of glycemic control status in patients with hemolytic anemia. Clin Chim Acta 2011, 412:253-257.
52. Kosecki S.M., Rodgers P.T., Adams M.B. Glycemic monitoring in diabetics with sickle cell plus beta-thalassemia hemoglobinopathy. Ann Pharmacother 2005, 39:1557-1560.
53. Lee E.Y., Lee B.W., Kim D., Lee Y.H., Kim K.J., Kang E.S., et al. Glycated albumin is a useful glycation index for monitoring fluctuating and poorly controlled type 2 diabetic patients. Acta Diabetol 2011, 48:167-172.
54. Kumeda Y., Inaba M., Shoji S., Ishimura E., Inariba H., Yabe S., et al. Significant correlation of glycated albumin, but not glycated haemoglobin, with arterial stiffening in haemodialysis patients with type 2 diabetes. Clin Endocrinol (Oxf) 2008, 69:556-561.
55. Yamada S., Inaba M., Shidara K., Okada S., Emoto M., Ishimura E., et al. Association of glycated albumin, but not glycated hemoglobin, with peripheral vascular calcification in hemodialysis patients with type 2 diabetes. Life Sci 2008, 83:516-519.
56. Hwang J.S., Shin C.H., Yang S.W. Clinical implications of N epsilon-(carboxymethyl)lysine, advanced glycation end product, in children and adolescents with type 1 diabetes. Diabetes Obes Metab 2005, 7:263-267.
57. Kerkeni M., Saidi A., Bouzidi H., Letaief A., Ben Yahia S., Hammami M. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients. Diab Vasc Dis Res 2012, 10.1177/1479164112460253.
58. Schram M.T., Schalkwijk C.G., Bootsma A.H., Fuller J.H., Chaturvedi N., Stehouwer C.D. Advanced glycation end products are associated with pulse pressure in type 1 diabetes: the EURODIAB prospective complications study. Hypertension 2005, 46:232-237.
59. Wautier M.P., Massin P., Guillausseau P.J., Huijberts M., Levy B., Boulanger E., et al. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients. Diabetes Metab 2003, 29:44-52.
60. Yoshida N., Okumura K., Aso Y. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism 2005, 54:345-350.
61. Nin J.W., Jorsal A., Ferreira I., Schalkwijk C.G., Prins M.H., Parving H.H., et al. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care 2011, 34:442-447.
62. Boehm B.O., Schilling S., Rosinger S., Lang G.E., Lang G.K., Kientsch-Engel R., et al. Elevated serum levels of N(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema. Diabetologia 2004, 47:1376-1379.
63. Ghanem A.A., Elewa A., Arafa L.F. Pentosidine and N-carboxymethyl-lysine: biomarkers for type 2 diabetic retinopathy. Eur J Ophthalmol 2011, 21:48-54.
64. Kerkeni M., Saidi A., Bouzidi H., Yahya S.B., Hammami M. Elevated serum levels of AGEs, sRAGE, and pentosidine in Tunisian patients with severity of diabetic retinopathy. Microvasc Res 2012, 84:378-383.
65. Sato E., Nagaoka T., Yokota H., Takahashi A., Yoshida A. Correlation between plasma pentosidine concentrations and retinal hemodynamics in patients with type 2 diabetes. Am J Ophthalmol 2012, 153:903-909.
66. Lapolla A., Reitano R., Baccarin L., Sartore G., Plebani M., Fedele D. Pentosidine plasma levels and relation with metabolic control in diabetic patients. Horm Metab Res 2005, 37:252-256.
67. Furuya R., Kumagai H., Miyata T., Fukasawa H., Isobe S., Kinoshita N., et al. High plasma pentosidine level is accompanied with cardiovascular events in hemodialysis patients. Clin Exp Nephrol 2012, 16:421-426.
68. Zhou Y., Yu Z., Jia H., Sun F., Ma L., Guo R., et al. Association of serum pentosidine with arterial stiffness in hemodialysis patients. Artif Organs 2010, 34:193-199.
69. Lieuw A.F.M.L., van Hinsbergh V.W., Teerlink T., Barto R., Twisk J., Stehouwer C.D., et al. Increased levels of N(epsilon)-(carboxymethyl)lysine and N(epsilon)-(carboxyethyl)lysine in type 1 diabetic patients with impaired renal function: correlation with markers of endothelial dysfunction. Nephrol Dial Transplant 2004, 19:631-636.
70. Wagner Z., Molnar M., Molnar G.A., Tamasko M., Laczy B., Wagner L., et al. Serum carboxymethyllysine predicts mortality in hemodialysis patients. Am J Kidney Dis 2006, 47:294-300.
71. Koyama Y., Takeishi Y., Arimoto T., Niizeki T., Shishido T., Takahashi H., et al. High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J Card Fail 2007, 13:199-206.
72. Ikeda T., Maruyama K., Ito N., Utagawa A., Nagane M., Shiokawa Y. Serum pentosidine, an advanced glycation end product, indicates poor outcomes after acute ischemic stroke. J Stroke Cerebrovasc Dis 2012, 21:386-390.
73. Willemsen S., Hartog J.W., van Veldhuisen D.J., van der Meer P., Roze J.F., Jaarsma T., et al. The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction. Am Heart J 2012, 164:742-749.
74. Dworacka M., Winiarska H., Szymanska M., Szczawinska K., Wierusz-Wysocka B. Serum N-epsilon-(carboxymethyl)lysine is elevated in nondiabetic coronary heart disease patients. J Basic Clin Physiol Pharmacol 2002, 13:201-213.
75. Semba R.D., Najjar S.S., Sun K., Lakatta E.G., Ferrucci L. Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am J Hypertens 2009, 22:74-79.
76. Kaufmann E., Boehm B.O., Sussmuth S.D., Kientsch-Engel R., Sperfeld A., Ludolph A.C., et al. The advanced glycation end-product N epsilon-(carboxymethyl)lysine level is elevated in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Neurosci Lett 2004, 371:226-229.
77. Sternberg Z., Hennies C., Sternberg D., Bistulfi G.L., Kazim L., Benedict R.H., et al. Plasma pentosidine: a potential biomarker in the management of multiple sclerosis. Mult Scler 2011, 17:157-163.
78. Meli M., Perier C., Ferron C., Parssegny F., Denis C., Gonthier R., et al. Serum pentosidine as an indicator of Alzheimer's disease. J Alzheimers Dis 2002, 4:93-96.
79. Ni J., Yuan X., Gu J., Yue X., Gu X., Nagaraj R.H., et al. Plasma protein pentosidine and carboxymethyllysine, biomarkers for age-related macular degeneration. Mol Cell Proteomics 2009, 8:1921-1933.
80. Hein G.E., Kohler M., Oelzner P., Stein G., Franke S. The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis. Rheumatol Int 2005, 26:137-141.
81. Senolt L., Braun M., Vencovsky J., Sedova L., Pavelka K. Advanced glycation end-product pentosidine is not a relevant marker of disease activity in patients with rheumatoid arthritis. Physiol Res 2007, 56:771-777.
82. Vos P.A., DeGroot J., Huisman A.M., Oostveen J.C., Marijnissen A.C., Bijlsma J.W., et al. Skin and urine pentosidine weakly correlate with joint damage in a cohort of patients with early signs of osteoarthritis (CHECK). Osteoarthritis Cartilage 2010, 18:1329-1336.
83. Busch M., Franke S., Wolf G., Brandstadt A., Ott U., Gerth J., et al. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension. Am J Kidney Dis 2006, 48:571-579.
84. Monnier V.M., Bautista O., Kenny D., Sell D.R., Fogarty J., Dahms W., et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT skin collagen ancillary study group. Diabetes control and complications trial. Diabetes 1999, 48:870-880.
85. Mitome J., Yamamoto H., Saito M., Yokoyama K., Marumo K., Hosoya T. Nonenzymatic cross-linking pentosidine increase in bone collagen and are associated with disorders of bone mineralization in dialysis patients. Calcif Tissue Int 2011, 88:521-529.
86. Meerwaldt R., Lutgers H.L., Links T.P., Graaff R., Baynes J.W., Gans R.O., et al. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 2007, 30:107-112.
87. Noordzij M.J., Mulder D.J., Oomen P.H., Brouwer T., Jager J., Castro Cabezas M., et al. Skin autofluorescence and risk of micro- and macrovascular complications in patients with type 2 diabetes mellitus-a multi-centre study. Diabet Med 2012, 10.1111/dme.12005.
88. de Vos L.C., Noordzij M.J., Mulder D.J., Smit A.J., Lutgers H.L., Dullaart R.P., et al. Skin autofluorescence as a measure of advanced glycation end products deposition is elevated in peripheral artery disease. Arterioscler Thromb Vasc Biol 2013, 33:131-138.
89. Fosmark D.S., Berg J.P., Jensen A.B., Sandvik L., Agardh E., Agardh C.D., et al. Increased retinopathy occurrence in type 1 diabetes patients with increased serum levels of the advanced glycation endproduct hydroimidazolone. Acta Ophthalmol 2009, 87:498-500.
90. Fosmark D.S., Torjesen P.A., Kilhovd B.K., Berg T.J., Sandvik L., Hanssen K.F., et al. Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. Metabolism 2006, 55:232-236.
91. Kilhovd B.K., Juutilainen A., Lehto S., Ronnemaa T., Torjesen P.A., Hanssen K.F., et al. Increased serum levels of methylglyoxal-derived hydroimidazolone-AGE are associated with increased cardiovascular disease mortality in nondiabetic women. Atherosclerosis 2009, 205:590-594.
92. Ahmed N., Thornalley P.J., Dawczynski J., Franke S., Strobel J., Stein G., et al. Methylglyoxal-derived hydroimidazolone advanced glycation end-products of human lens proteins. Invest Ophthalmol Vis Sci 2003, 44:5287-5292.
93. Gomes R., Sousa Silva M., Quintas A., Cordeiro C., Freire A., Pereira P., et al. Argpyrimidine, a methylglyoxal-derived advanced glycation end-product in familial amyloidotic polyneuropathy. Biochem J 2005, 385:339-345.
94. Descamps-Latscha B., Witko-Sarsat V., Nguyen-Khoa T., Nguyen A.T., Gausson V., Mothu N., et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005, 45:39-47.
95. Kaneda H., Taguchi J., Ogasawara K., Aizawa T., Ohno M. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 2002, 162:221-225.
96. Witko-Sarsat V., Friedlander M., Capeillere-Blandin C., Nguyen-Khoa T., Nguyen A.T., Zingraff J., et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996, 49:1304-1313.
97. Ringman J.M., Fithian A.T., Gylys K., Cummings J.L., Coppola G., Elashoff D., et al. Plasma methionine sulfoxide in persons with familial Alzheimer's disease mutations. Dement Geriatr Cogn Disord 2012, 33:219-225.
98. Tohgi H., Abe T., Yamazaki K., Murata T., Ishizaki E., Isobe C. Alterations of 3-nitrotyrosine concentration in the cerebrospinal fluid during aging and in patients with Alzheimer's disease. Neurosci Lett 1999, 269:52-54.
99. Morgan P.E., Sturgess A.D., Davies M.J. Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus. Arthritis Rheum 2005, 52:2069-2079.
100. Misko T.P., Radabaugh M.R., Highkin M., Abrams M., Friese O., Gallavan R., et al. Characterization of nitrotyrosine as a biomarker for arthritis and joint injury. Osteoarthritis Cartilage 2012, 10.1016/j.joca.2012.09.005.
101. Eleuteri E., Di Stefano A., Ricciardolo F.L., Magno F., Gnemmi I., Colombo M., et al. Increased nitrotyrosine plasma levels in relation to systemic markers of inflammation and myeloperoxidase in chronic heart failure. Int J Cardiol 2009, 135:386-390.
102. Campos C., Guzman R., Lopez-Fernandez E., Casado A. Evaluation of urinary biomarkers of oxidative/nitrosative stress in adolescents and adults with Down syndrome. Biochim Biophys Acta 1812, 2011:760-768.
103. Hazen S.L., Heinecke J.W. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 1997, 99:2075-2081.
104. Leeuwenburgh C., Hardy M.M., Hazen S.L., Wagner P., Oh-ishi S., Steinbrecher U.P., et al. Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J Biol Chem 1997, 272:1433-1436.
105. Leeuwenburgh C., Rasmussen J.E., Hsu F.F., Mueller D.M., Pennathur S., Heinecke J.W. Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. J Biol Chem 1997, 272:3520-3526.
106. Smith W.G., Holden M., Benton M., Brown C.B. Carbamylated haemoglobin in chronic renal failure. Clin Chim Acta 1988, 178:297-303.
107. Stim J., Shaykh M., Anwar F., Ansari A., Arruda J.A., Dunea G. Factors determining hemoglobin carbamylation in renal failure. Kidney Int 1995, 48:1605-1610.
108. Tarif N., Shaykh M., Stim J., Arruda J.A., Dunea G. Carbamylated hemoglobin in hemodialysis patients. Am J Kidney Dis 1997, 30:361-365.
109. Davenport A., Jones S.R., Goel S., Astley J.P., Hartog M. Differentiation of acute from chronic renal impairment by detection of carbamylated haemoglobin. Lancet 1993, 341:1614-1617.
110. Wynckel A., Randoux C., Millart H., Desroches C., Gillery P., Canivet E., et al. Kinetics of carbamylated haemoglobin in acute renal failure. Nephrol Dial Transplant 2000, 15:1183-1188.
111. Apostolov E.O., Ray D., Savenka A.V., Shah S.V., Basnakian A.G. Chronic uremia stimulates LDL carbamylation and atherosclerosis. J Am Soc Nephrol 2010, 21:1852-1857.
112. Condezo-Hoyos L., Rubio M., Arribas S.M., Espana-Caparros G., Rodriguez-Rodriguez P., Mujica-Pacheco E., et al. A plasma oxidative stress global index in early stages of chronic venous insufficiency. J Vasc Surg 2012, 10.1016/j.jvs.2012.05.085.
113. Pamplona R., Naudi A., Gavin R., Pastrana M.A., Sajnani G., Ilieva E.V., et al. Increased oxidation, glycoxidation, and lipoxidation of brain proteins in prion disease. Free Radic Biol Med 2008, 45:1159-1166.
114. Pamplona R., Portero-Otin M., Bellmun M.J., Gredilla R., Barja G. Aging increases Nepsilon-(carboxymethyl)lysine and caloric restriction decreases Nepsilon-(carboxyethyl)lysine and Nepsilon-(malondialdehyde)lysine in rat heart mitochondrial proteins. Free Radic Res 2002, 36:47-54.